News and Community

Drug Administration, Drug Substance, Healthcare Technology, Mfg8, Pli Pass, Wuxi Biologics

July 9, 2026

WuXi Biologics MFG8 Drug Substance Facility Achieves FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy

Chief Medical Officer, Drug Administration, Genentech, Healthcare Technology, Kras G12c, Oncology

July 2, 2026

Genentech’s Divarasib Proves Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer

Aav-based Gene Therapies, Domestic Pharmaceutical, Drug Administration, Drug Supply Chain, Healthcare Technology, Pilot Program

June 30, 2026

FDA Chooses Kriya Therapeutics for Next-Generation Medical Pilot Program